Lexicon Pharmaceuticals Inc
NASDAQ:LXRX

Watchlist Manager
Lexicon Pharmaceuticals Inc Logo
Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Watchlist
Price: 0.7455 USD 3.46% Market Closed
Market Cap: 270.8m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

LXRX Price Targets Summary
Lexicon Pharmaceuticals Inc

Wall Street analysts forecast LXRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LXRX is 2.6316 USD with a low forecast of 0.707 USD and a high forecast of 6.3 USD.

LXRX Lowest Forecast
Wall Street Target
0.707 USD
5% Downside
LXRX Average Forecast
Wall Street Target
2.6316 USD
253% Upside
LXRX Highest Forecast
Wall Street Target
6.3 USD
745% Upside
Lowest
Price Target
0.707 USD
5% Downside
Average
Price Target
2.6316 USD
253% Upside
Highest
Price Target
6.3 USD
745% Upside
Lexicon Pharmaceuticals Inc Competitors:
Price Targets
VCYT
Veracyte Inc
59% Upside
J
7774
Japan Tissue Engineering Co Ltd
104% Upside
300009
Anhui Anke Biotechnology Group Co Ltd
33% Upside
RYTM
Rhythm Pharmaceuticals Inc
37% Upside
VCYT
Veracyte Inc
59% Upside
J
7774
Japan Tissue Engineering Co Ltd
104% Upside
300009
Anhui Anke Biotechnology Group Co Ltd
33% Upside
RYTM
Rhythm Pharmaceuticals Inc
37% Upside
4
4BB
4Basebio PLC
76% Upside
M
MAB
Mabion SA
3% Downside
DTIL
Precision BioSciences Inc
367% Upside
ACAD
ACADIA Pharmaceuticals Inc
19% Upside

Revenue
Forecast

Revenue Estimate
Lexicon Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Lexicon Pharmaceuticals Inc's revenue is -11%. The projected CAGR for the next 3 years is 17%.

-11%
Past Growth
17%
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Lexicon Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Lexicon Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-61%
Average Miss
What are analyst estimates?

See Also

Summary
LXRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LXRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LXRX stock valuation using valuation multiples.
Wall Street Estimates
LXRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LXRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LXRX's stock price target?
Price Target
2.6316 USD

According to Wall Street analysts, the average 1-year price target for LXRX is 2.6316 USD with a low forecast of 0.707 USD and a high forecast of 6.3 USD.

What is Lexicon Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Lexicon Pharmaceuticals Inc's revenue is -11%. The projected CAGR for the next 3 years is 17%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 262,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.